2-Aminoindane (2-AI) is a
research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a
designer drug.[1] It acts as a selective substrate for
NET and
DAT.[2][3]
Therapeutic and illicit uses
Synthetic aminoindanes were originally developed in the context of
anti-Parkinsonian drugs as a metabolite of
rasagiline and as a tool to be used in
psychotherapy. Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters.[4] 2-AI is a rigid
analogue of
amphetamine and partially substitutes for it in
ratdiscrimination tests.[5]
As of October 2015 2-AI is a controlled substance in China.[6]
Sweden
Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.[7]
United States
2-Aminoindane is not scheduled at the federal level in the
United States,[8] but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the
Federal Analog Act.
^Oberlender R, Nichols DE (March 1991). "Structural variation and (+)-amphetamine-like discriminative stimulus properties". Pharmacology, Biochemistry, and Behavior. 38 (3): 581–6.
doi:
10.1016/0091-3057(91)90017-V.
PMID2068194.
S2CID19069907.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" [On the issuance of non-pharmaceutical narcotic drugs and psychotropic substances listed in the notice] (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from
the original on 1 October 2015. Retrieved 1 October 2015.